Overview

Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids

Status:
Terminated
Trial end date:
2019-10-09
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of naloxegol (Movantik) to a laxative protocol in critically ill adults requiring scheduled opioid (e.g. fentanyl) therapy. Half of the participants will receive naloxegol and a laxative protocol and half the participants will receive a placebo and a laxative protocol.
Phase:
Phase 4
Details
Lead Sponsor:
Tufts Medical Center
Treatments:
Analgesics, Opioid
Bisacodyl
Bismuth subsalicylate
Citric Acid
Magnesium citrate
Methylnaltrexone
Naloxegol
Naltrexone
Polyethylene glycol 3350
Senna Extract
Sennoside A&B